Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ablynx NV Announces Collaboration with Merck & Co Inc to Develop Therapeutic Nanobody Candidates


Tuesday, 2 Oct 2012 01:31am EDT 

Ablynx NV announced a collaboration with Merck & Co Inc., through a subsidiary, to develop and commercialize Nanobody candidates directed towards a voltage gated ion channel with the option to develop and commercialize a Nanobody to a second target. Merck & Co Inc is known as MSD outside the United States and Canada. Under the terms of the agreement, Merck & Co Inc gains exclusive global rights to Nanobodies against the selected target, with an option for similar rights to a second target. Upon signing, Merck & Co Inc will pay Ablynx NV a EUR 6.5 million upfront payment and a EUR 2 million fee for research funding. In addition, Ablynx NV will be eligible to receive up to EUR 448 million in research, regulatory and commercial milestone payments associated with the progress of multiple candidates as well as tiered royalties on any products derived from the collaboration. Ablynx NV will be responsible for the discovery of Nanobody candidates and Merck & Co Inc will be responsible for the research, development, manufacturing and commercialization of any Nanobody product resulting from the collaboration. 

Company Quote

57.03
-1.05 -1.81%
3:15pm EDT